Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for tough liver cancer

NCT ID NCT02519348

Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease. While not a cure, the approach aims to give patients more time and better control over their cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

433 people

The number who actually took part.

Started

Oct 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants 2. 18 years and older (Japan-20 years and older) 3. Confirmed hepatocellular carcinoma (HCC) based on histopathological findings from tumor tissues. Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods. 4. Immunotherapy-naïve 5. Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI. For arm 5 only: Have not received any prior systemic therapy for HCC. Exclusion Criteria: 1. Prior exposure to immune-mediated therapy 2. Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy 3. Gastrointestinal bleeding (eg, esophageal varices or ulcer bleeding) within 12 months 4. Ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose. 5. Main portal vein thrombosis (Vp4) as documented on imaging 6. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment 7. Active or prior documented autoimmune or inflammatory disease with some exceptions 8. Current or prior use of immunosuppressive medication within 14 days with some exceptions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    San Francisco, California, 94158, United States

  • Research Site

    New Haven, Connecticut, 06510, United States

  • Research Site

    Jacksonville, Florida, 32224, United States

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Indianapolis, Indiana, 46202, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Stony Brook, New York, 11794, United States

  • Research Site

    Durham, North Carolina, 27705, United States

  • Research Site

    Portland, Oregon, 97213, United States

  • Research Site

    Philadelphia, Pennsylvania, 19107, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Dallas, Texas, 75390, United States

  • Research Site

    Seattle, Washington, 98109, United States

  • Research Site

    Hangzhou, 310016, China

  • Research Site

    Nanjing, 210002, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Shatin, Hong Kong

  • Research Site

    Benevento, 82100, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Osakasayama-shi, 589-8511, Japan

  • Research Site

    Bukit Merah, 169610, Singapore

  • Research Site

    Singapore, 119074, Singapore

  • Research Site

    Singapore, 308433, Singapore

  • Research Site

    Busan, 49241, South Korea

  • Research Site

    Junggu, 41944, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06273, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Kaohsiung City, 83301, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taoyuan City, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.